Table 5.
Characteristics of Early Clinical Studies
| Author /year |
Sample size |
Nature | Embolicagent | Embolic size (µm) |
Diabetes | Follow -up (months) |
Endoscopy | Primary endpoint |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Gunn AJ/2014 [46] | 19 | R | Coils, gelfoam, PVA | 300–500 | Unknown | 13.6 | Unknown | Weight loss |
| 500–710 | ||||||||
| 710–1000 | ||||||||
|
| ||||||||
| Anton K/2014 [47] | 10 | R | Coils, gelatin sponge pledget suspension | Unknown | Included | 12 | Unknown | Weight loss |
|
| ||||||||
| Kipshidze N/2015 [48] | 5 | P | Bead Block | 300–500 | Unknown | 24 | Day after procedure | Weight loss |
|
| ||||||||
| Syed MI/2016 [49] | 4 | P | Bead Block | 300–500 | Included | 6 | Baseline and 3 days post-procedure | Safety |
|
| ||||||||
| Weiss CR/2017 [50] | 5 | P | Embosphere | 300–500 | Excluded | 3 | Baseline, 2 weeks, and 3 months post-procedure | 30-day AEs |
|
| ||||||||
| Bai ZB/2017 [51] | 5 | P | PVA | 500–710 | Included | 9 | Baseline and 3 days post-procedure | Safety |
R, retrospective; P, prospective; PVA, polyvinyl alcohol; AEs, adverse events